Abstract
One hundred and eleven patients with non-A, non-B/type C (NANB/C) chronic active hepatitis were randomly assigned to two groups to receive recombinant interferon alfa-2b treatment as follows: 3 million units (MU) interferon three times weekly for six months or 3 MU interferon three times weekly for the first six months, 2 MU for the next three months, and 1 MU for the last three months. At the end of treatment, the number who had responded completely was similar in both groups (47.2% in the six months group v 41.4% in the 12 months group). Cirrhosis was found to be the only predictive factor for response; a complete response was observed in 50.6% of patients without cirrhosis v 33.3% of those with cirrhosis (p = 0.04). After one year of treatment, the rate of relapse was lower in patients who had received longer treatment (33%) than in those who had received six months of interferon (60%). The difference between the groups was not statistically significant and the trend favouring longer treatment for sustained response requires further confirmation.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Davis G. L., Balart L. A., Schiff E. R., Lindsay K., Bodenheimer H. C., Jr, Perrillo R. P., Carey W., Jacobson I. M., Payne J., Dienstag J. L. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med. 1989 Nov 30;321(22):1501–1506. doi: 10.1056/NEJM198911303212203. [DOI] [PubMed] [Google Scholar]
- Di Bisceglie A. M., Martin P., Kassianides C., Lisker-Melman M., Murray L., Waggoner J., Goodman Z., Banks S. M., Hoofnagle J. H. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med. 1989 Nov 30;321(22):1506–1510. doi: 10.1056/NEJM198911303212204. [DOI] [PubMed] [Google Scholar]
- Lunel-Fabiani F., Guivarch P., Valla D., Grippon P., Marques M. A., Huraux J. M., Le Charpentier Y., Levy V. G., Bousquet O., Opolon P. Traitement par l'interféron alpha-2a de 26 cas d'hépatites chroniques non A-non B. Etude des facteurs prédictifs de réponse. Gastroenterol Clin Biol. 1990;14(10):705–709. [PubMed] [Google Scholar]
- Marcellin P., Boyer N., Giostra E., Degott C., Courouce A. M., Degos F., Coppere H., Cales P., Couzigou P., Benhamou J. P. Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology. 1991 Mar;13(3):393–397. [PubMed] [Google Scholar]
- Shindo M., Di Bisceglie A. M., Cheung L., Shih J. W., Cristiano K., Feinstone S. M., Hoofnagle J. H. Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Ann Intern Med. 1991 Nov 1;115(9):700–704. doi: 10.7326/0003-4819-115-9-700. [DOI] [PubMed] [Google Scholar]